Clinical Trial Update: Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

View source ↗

Summary

Expanded Access study of Alectinib for ALK-rearranged non-small cell lung cancer after progression on or intolerance to prior ALK inhibitors; the trial is no lo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alecensa (alectinib)

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-Small Cell Lung Cancer | Status: NO_LONGER_AVAILABLE